Sedogen announces issuance of new U.S. patent for the use of diazoxide formulations to treat behavioral symptoms in Prader-Willi syndrome

CHICAGO, April 15, 2026 /PRNewswire/ -- Sedogen LLC, a biopharmaceutical company dedicated to improving the lives of individuals and families affected by Prader-Willi syndrome, announced today the issuance of a new patent (12,589,098) from the U.S. Patent and Trademark Office related to...